PharmaEssentia Corporation announced the Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia (ET). New drug name or code: Ropeginterferon alfa-2b(P1101). NCT Number: NCT04285086.

Planned development stages: To complete the phase III clinical trial, and later to apply for the marketing authorization. Current development stage: The enrollment of the phase III clinical trial of Ropeginterferon alfa-2b for the treatment of essential thrombocythemia (ET) is officially completed, and 174 subjects were enrolled in the trial. Upcoming development plan: To continue the phase III clinical trial of Ropeginterferon alfa-2b for ET.

Estimated date of completion: Data collection of the primary endpoint for the phase III clinical trial of Ropeginterferon alfa-2b for ET is expected to be completed in 2024; the timeline will be adjusted according to the actual progress of the clinical trial, and disclosure will be made upon the progress of the study according to the regulations. Ropeginterferon alfa-2b is approved to treat adult patients with PV in the European Union, Taiwan, Switzerland, Israel, South Korea, Macao, United States, Japan, Bahrain, and Qatar. New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks.

The investors are advised to exercise caution and conduct thorough evaluation.